Credit: Getty Images. Tepezza is a human insulin-like growth factor-1 receptor inhibitor. Tepezza ® (teprotumumab-trbw) significantly reduced proptosis in adults with chronic thyroid eye disease (TED) ...

A 78-year-old woman was referred to the neuro-ophthalmology service at New England Eye Center for several months of progressive diplopia, bilateral eye redness and proptosis. The patient’s medical ...

Please provide your email address to receive an email when new articles are posted on . A 34-year-old woman was transferred to the University of New Mexico emergency department with a 3-day history of ...

Batoclimab did not significantly improve proptosis responder rates vs placebo in patients with thyroid eye disease at week 24. Topline data were announced from two phase 3 trials evaluating batoclimab ...

Of the 655 patients enrolled in this study, 89 (13.5%) (95% confidence interval [CI] 15%-10%) presented with unilateral exophthalmos. Exophthalmometer values in the ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

The differential diagnosis of childhood proptosis includes several potential life-threatening or vision-threatening diseases that must not be missed. It includes the following: Orbital lymphangioma is ...

Bulging Eyes refers to the abnormal protrusion or sticking out of one or both eyeballs from the eye socket. Normally, there should be no visible white between the colored part of the eye and the upper ...

DUBLIN--(BUSINESS WIRE)--Horizon Pharma plc (Nasdaq: HZNP) today announced that new data from the Phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for ...

Dr. Mark A. Matza (Medicine): An 18-year-old man was evaluated at this hospital because of diplopia and proptosis of the left eye. The patient had been well until approximately 33 months before this ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...